Study for lung cancer with brain spread and EGFR mutation
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a treatment for people with advanced non-small cell lung cancer that has spread to the brain or spine. It is for those whose cancer has a specific EGFR mutation (19Del or L858R) and who have not yet received treatment for their advanced cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with advanced non-small cell lung cancer that has not been treated yet.
- Your cancer has an EGFR mutation (either 19Del or L858R).
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You are willing to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
This trial collects tissue samples from your lung tumor and any tumors that have spread to other parts of your body. They will study the genetic makeup of these samples to better understand lung cancer and improve future treatments.
This trial studies how well targeted therapy works for advanced non-small cell lung cancer (NSCLC) that has spread. You may qualify if you have a specific gene change and are starting your first targeted treatment.
This trial tests a new drug, HSK40118, for people with advanced non-small cell lung cancer (NSCLC) that has an EGFR mutation and has been treated with certain EGFR-targeted therapies before. The goal is to see if this drug can help when other treatments stop working.
This trial tests a combination of low-dose radiation to the whole brain, immunotherapy, and chemotherapy given through a lumbar puncture. It is for people with lung cancer that has spread to the lining of the brain and has not responded to standard treatments.
This trial tests a targeted pill (Limertinib) combined with radiation therapy for people with a specific type of lung cancer (EGFR mutation) that has spread to the brain. The goal is to see if this combination shrinks brain tumors and keeps them from growing.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.